Dr. Ronald (Ron) Krall is a board-certified neurologist and clinical pharmacologist with significant and varied pharmaceutical experience at the senior executive level. He has worked with Lorex Pharmaceuticals, Abbott Laboratories, ZENECA, AstraZeneca, and GlaxoSmithKline (GSK). While serving as Chief Medical Officer for GSK, Dr. Krall had leadership responsibility for the company’s worldwide development, regulatory affairs, drug safety, and medical ethics. His work included oversight for development of several major drugs, including oncology drugs (Ambien, Depakote, Nolvadex, Faslodex, Arimidex, Iressa, Tykerb, Seroquel, and Accolate). He was a lengthy contributing member of the Academy of Medicine’s Forum for Drug Discovery, Development, and Translation. As a widely respected senior development and policy executive with a very strong experience in product development, he has gained a deep understanding of the importance and utility of actionable diagnostic data to treatment selection.
Dr. Krall received his BA from Swarthmore College and his MD from the University of Pittsburgh. He did his residency and fellowship training at Los Angeles Harbor General Hospital, the NIH and the University of Rochester. He currently serves as Adjunct Professor of Neurology at the University of Rochester, as Senior Advisor for the investment firm Propel BioPartners, and as a Director of the Foundation of the National Institutes of Health.
Robert Henry is leading another healthcare turnaround success story as Chief Executive Officer at Pierian Biosciences where he is applying his experience in growing, building, and rejuvenating healthcare companies. He joined Pierian Biosciences (formerly DiaTech Oncology) in 2013 to take the company to the next level in the personalized cancer care market. He brought more than twenty-five years of healthcare management experience in developing, implementing, and evaluating new opportunities in managed care. He has excelled as a business development leader, president, CEO, and board member with extensive qualifications in operational and financial management, management restructuring, contract negotiations, and international governance.
Previously, he served as SVP of Development at Symbion, Inc., President and Chief Executive Officer of American Endoscopy Services, and Chief Operating Officer of Physician Alliances.
Henry holds an MBA from the Owen Graduate School of Management at Vanderbilt University and a BS in Business Administration-Finance from the University of Tennessee.
Dr. Craig Eagle enjoys a long and successful career in the international pharmaceutical industry with senior executive experience in both large and small biotech companies. Currently the Chief Medical Officer at Guardant Health, he has international experience with multiple health care systems as an oncologist and hematopathologist, clinical trial experience (Phase I-IV) directed at the development and approval of oncology products, leadership team driving the regulatory approvals of new oncology drugs and their associated diagnostics. He has led, or been directly involved with, teams that resulted in eight new products or indications, and the integration of the Pfizer/Wyeth oncology businesses and portfolio.
As Vice President of Strategic Alliances and Partnerships for the oncology business unit at Pfizer Inc. and as Director at Generex Biotechnology Corp., Regenicin, Inc., and Assured Pharmacy Inc., Dr. Eagle’s responsibilities have exclusively focused on managing the growth of the companies’ global oncology business through external and internal research, strategic alliances, and M&A oncology acquisitions.
Dr. Eagle’s wealth of oncology experience includes leading and participating in scientific research, regulatory pricing & re-imbursement negotiations for compounds in therapeutic areas, worldwide development of Celecoxib in oncology, global research Dalteparin, serving as Head of the Oncology Therapeutic Area Global Medical Group for Pfizer, and as a Member of Scientific Advisory Board at Generex Biotechnology Corp.
Dr. Eagle attended medical school at the University of New South Wales, Sydney, Australia and received his general internist training at Royal North Shore Hospital in Sydney. He completed his hemato-oncology and laboratory hematology training at Royal Prince Alfred Hospital in Sydney. He was granted Fellowship in the Royal Australasian College of Physicians and the Royal College of Pathologists Australasia.
The President Emeritus and Senior Scholar of The New York Academy of Medicine, she has and continues to lead its strategic vision for health equity. Dr. Salerno is one of the nation’s pre-eminent leaders in health and healthcare and has demonstrated an unwavering commitment to assuring that everyone has the opportunity to live a healthy unifying theme of her career, during which she has those living with metastatic breast cancer, Medicaid recipients, and Alzheimer’s patients.
Prior to joining NYAM, Dr. Salerno served as President and Chief Executive Officer of Susan G. Komen TM, the world’s largest breast cancer organization. She also served as the Leonard D. Schaeffer Executive Officer of the Institute of Medicine of the National Academies, Deputy Director of the National Institute on Aging at the National Institutes of Health, and Chief Consultant for Geriatrics and Extended Care for the U.S. Veterans Health Administration. Dr. Salerno is a board-certified physician in internal medicine and holds an MD degree from Harvard Medical School and a Master of Science in Health Policy from the Harvard School of Public Health. She was elected a member of the National Academy of Medicine in 2018 and was elected as a Fellow of The New York Academy of Medicine in 2017.
Dr. Salerno is the recipient of numerous awards and honors including the Meritorious Service Award, U.S. Department of Veterans Affairs (2001); NIH Director’s Award (2003, 2005, 2008); Surgeon General’s Crisis Response Service Award, U.S. Public Health Service (2006); Harvard T.H. Chan School of Public Health Award of Merit (2020); and Community Service Award, Crohn’s and Colitis Foundation of Greater Washington D.C. (2020). She was also a 2019 National Honoree of the National Organization of Italian American Women, was recognized by City & State New York on its Health Power 50 list in 2019 and 2020, whilst also receiving a Doctor of Humane Letters (hon.) from Stonehill College in 2021.
Mr. Andrew (Andy) W. Miller, Jr. is a Managing Partner at Miller Companies and served as chairman of several companies in Health Care Services, Pharmaceutical, Technology, and Diagnostic areas.
Mr. Miller started his career as a private investor in the year 2000. He spent Institutional Broker/Trader focused exclusively on health care services. The group he founded while there became the fifth most profitable division of the investment banking firm Donaldson, Lufkin, and Jenrette, before his exit in 1999.
Over the last twenty two years, Mr. Miller funded and managed his private investment firm which has, in turn, founded and managed over 25 new companies. He has served as chairman of over 10 companies and has created over a billion dollars of value, based on conservative accounting principles.
Mr. Miller’s specific focus has been, and will continue to be, health care solutions. He has also proven himself to be a “turnaround” specialist, having taken potential loss positions and, on average, created over 200% in returns.
Mr. Miller received his BA in Economics from Belmont University and later received an MBA from Vanderbilt’s Owen School of Business Management.